文献速递胸部肿瘤支持与姑息治疗

胸部放化疗与免疫治疗时代的心脏放射敏感性:范围综述

Cardiac radiosensitivity in the era of thoracic chemoradiotherapy and immunotherapy: a scoping review.
PubMed 文献 · Lancet Oncol · 2026-01-01

本范围综述探讨不可切除III期非小细胞肺癌(NSCLC)同步放化疗后免疫检查点抑制剂(ICI)巩固治疗标准背景下,放化疗与ICI各自及联合的心脏毒性。

要点

  • 放化疗与ICI联合构成新的心脏风险谱,二者独立心脏毒性可能叠加。
  • 需明确心脏亚区放射敏感性及ICI对放疗心脏毒性的影响。
  • 证据主要限于NSCLC,长期生存者、先进放疗技术和淋巴细胞减少交互作用待研究。

核心结论

  • 放化疗与ICI的联合代表一种新的心脏风险谱,需通过更大规模长期研究平衡肿瘤疗效与心血管安全。

主要发现

  • 综述分别考察放化疗相关和ICI相关心脏毒性,并评估二者在联合治疗中的汇聚效应。
  • 围绕六个关键问题展开:ICI是否增加放化疗心脏风险、既往放疗是否增加ICI心脏风险、ICI是否改变心脏亚区放射敏感性、心脏终点如何定义、分子或药理干预能否减轻毒性、主要风险因素与管理策略。
  • 指出四个主要空白:超越NSCLC的扩展、长期生存、先进放疗技术的潜力、淋巴细胞减少与心脏毒性的相互作用。

临床怎么用

  • 在胸部放化疗联合ICI的临床决策中,应关注心脏毒性风险,谨慎评估心血管安全。

局限性

  • 证据主要来自NSCLC,长期生存者数据有限,先进放疗技术应用潜力未充分明确。
  • 淋巴细胞减少与心脏毒性交互作用尚不清晰。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Concurrent chemoradiotherapy followed by immune checkpoint inhibitor (ICI) consolidation is now the standard of care for unresectable stage III non-small-cell lung cancer (NSCLC) and is increasingly applied to other thoracic malignancies. Although survival outcomes have improved, concerns about cardiac toxicity have emerged, as both chemoradiotherapy and ICIs are independently cardiotoxic and their combined effects remain unclear. This scoping review first examines chemoradiotherapy-associated and ICI-associated cardiac toxicity separately, and then evaluates their convergence in combined chemoradiotherapy and ICI therapy. For this examination and evaluation, we draw on ten clinical studies, two reviews, and five preclinical reports that together address six key questions: (1) does ICI add cardiac risks to chemoradiotherapy, (2) does previous radiotherapy increase cardiac risks with ICI, (3) does ICI alter the radiosensitivity of cardiac subregions, (4) how should cardiac endpoints be defined, (5) can molecular or pharmacological interventions mitigate toxicity, and (6) what are the major risk factors and management strategies? We also highlight four major gaps: extension beyond NSCLC, long-term survivorship, the potential of advanced radiotherapy techniques, and the interplay between lymphopenia and cardiotoxicity. The convergence of chemoradiotherapy and ICIs represents a new cardiac risk profile. Addressing these questions through larger, long-term studies is essential to balance oncological efficacy with cardiovascular safety.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Kim Y, Bates JE, Yoon HI, et al. Cardiac radiosensitivity in the era of thoracic chemoradiotherapy and immunotherapy: a scoping review. Lancet Oncol. 2026. PMID: 41785903. doi:10.1016/S1470-2045(25)00651-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。